推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 藥品安全是社會(huì)廣泛關(guān)注的焦點(diǎn)問(wèn)題。為確保上市后的藥品安全，我國(guó)在監(jiān)管和檢驗(yàn)等方面采取了諸多舉措。全國(guó)人大代表、中恒集團(tuán)(17.07, 0.40, 2.40%)董事長(zhǎng)許淑清指出，中藥制劑多為復(fù)方制劑，在現(xiàn)有藥品質(zhì)量標(biāo)準(zhǔn)的基礎(chǔ)上很難確保中藥制劑質(zhì)量。
她認(rèn)為，中國(guó)藥典的藥材標(biāo)準(zhǔn)從1995年版至2010年版，整體水平提高不明顯。由于缺乏中藥材質(zhì)量標(biāo)準(zhǔn)的基礎(chǔ)研究，使中藥制劑的整體質(zhì)量標(biāo)準(zhǔn)也難以提高。不同地區(qū)生產(chǎn)的中藥、甚至同一企業(yè)不同時(shí)期生產(chǎn)的中藥差異很大，嚴(yán)重影響了中藥制劑的療效和聲譽(yù)。此外，中藥材與中藥制劑有毒有害物質(zhì)研究不清，也導(dǎo)致其控制不嚴(yán)。目前中國(guó)藥典中對(duì)中藥材有農(nóng)藥殘留檢測(cè)要求的品種不超過(guò)10個(gè)，檢測(cè)的農(nóng)藥殘留種類(lèi)也只有部分有機(jī)氯、有機(jī)磷和擬除蟲(chóng)菊酶類(lèi)農(nóng)藥共24種。
“中藥制劑成分復(fù)雜，至今大多數(shù)中草藥的有效成分仍未明確，因而無(wú)法按化學(xué)藥品質(zhì)量控制標(biāo)準(zhǔn)來(lái)制訂中成藥的質(zhì)量標(biāo)準(zhǔn)。而且，中藥制劑的原料生藥及飲片本身各種成分的含量有一定差異，在制成中成藥后，其質(zhì)量控制的難度進(jìn)一步加大。”許淑清建議，國(guó)家有關(guān)部門(mén)組織制訂中藥材質(zhì)量標(biāo)準(zhǔn)及中成藥質(zhì)量標(biāo)準(zhǔn)指導(dǎo)原則或指南，使中藥材與中藥制劑標(biāo)準(zhǔn)提高有據(jù)可依；國(guó)家制訂相應(yīng)政策鼓勵(lì)各方參與提高中藥材和中成藥質(zhì)量標(biāo)準(zhǔn)，應(yīng)使提高中藥材和中成藥質(zhì)量標(biāo)準(zhǔn)成為常態(tài)化的工作。
